fda stops tirzepatide Grants a New Indication for Obesity Management FDA Drops Latest Statement: Tirzepatide

Gallbladder disease is worth flagging separately

As underlying mechanisms, it has been reported that GLP-1 causes renal vasodilatation, increases renal blood flow, increases glomerular filtration rate, inhibits the Na + /H + exchanger 3 in proximal tubule and decreases sodium, bicarbonate and water reabsorption [12, 14]

GIPR rs1800437 has been associated in published research with differential GIP-axis signaling and, by extension, with altered response to GIP/GLP-1 dual agonists

After 64 weeks, adults taking the pill lost an average of 14% to 17% of body weight, with about one in three people losing 20% or more